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Abstract
Cytokines have been widely used as adjuvants and therapeutic agents in treatments of
human  diseases.  Despite  their  recognized  potential  as  drugs,  the  medical  use  of
cytokines has considerable drawbacks, mainly related to their low stability and short
half-life.  Such  intrinsic  limitations  imply  the  administration  of  high  doses,  often
prompting  toxicity,  undesirable  side  effects  and  greater  production  costs.  Here,  we
describe a new category of mechanically stable nanostructured cytokines (TNFand
CCL4/MIP-1)  that  resist  harsh  physicochemical  conditions  in  vitro (pH  and
temperature),  while  maintaining  functionality.  These  bio-functional  materials  are
produced  in  recombinant  cell  factories  through  cost-effective  and  fully  scalable
processes. Notably,  we demonstrate their prophylactic potential  in vivo showing they
protect zebrafish from a lethal infection by Pseudomonas aeruginosa.
Key  words: cytokines,  immunization,  zebrafish,  macrophages,  inclusion  bodies,
nanoparticles.
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Introduction
In the quest for safe, effective,  practical prophylactics  and therapeutics,  recombinant
proteins  are  provoking  wide  interest.  Prophylactics  such  as  subunit  vaccines  or
therapeutics such as immunostimulants, are examples of successfully produced proteins.
Both are functionally well-characterized products, which are superior to DNA vaccines
or inactivated/attenuated vaccines in terms of biosafety.  Additionally,  they are poorly
reactogenic and can be designed a la carte [1]. Heterologous protein expression systems
allow for easy and highly reproducible protein production at lower cost and at large
scale [2]. Such systems have been developed in bacteria (E. coli), yeast (S. cerevisiae),
insect cells (D. melanogaster cells), protozoa (Tetrahymena thermophila), mammalian
cell cultures or plants [3, 4]. In bacterial expression systems, in many cases, the desired
protein product needs to be extracted from inclusion bodies (IBs) and renaturalized to
obtain the soluble form. Recently IBs,  per se, have attracted interest as bio-materials
due to their high stability, withstanding extreme temperatures and lyophilization [5]. IBs
are protein clusters in the upper size of the nanoscale, ranging from 50 to 700 nm [6],
highly  enriched  with  the  recombinant  protein  itself  but  complex  in  composition,
including a spectrum of macromolecules from the producing cell. Nevertheless, IBs are
not inert and when exposed to mammalian cells penetrate the membrane and they issue
a sustained release of the protein they are comprised of, in a functional form, over time
[7]. This fact has been previously demonstrated with a diversity of proteins forming IBs,
including hormones, chaperones, enzymes, growth factors and cytoskeleton components
[7-10].  Most of the biological  and physicochemical  properties of IBs are moldable,
such as size, bio-adhesiveness, net charge, density and the release of functional protein
inside cells upon exposure [5, 11-13].  Importantly, the recombinant protein production
of IBs is fully scalable and the biofabrication process is cost-effective. 
Cytokines  are  proteins  with a  central  role  in  immunity  [14] and have been used as
adjuvants, immunostimulants and therapeutic agents in the treatment of human diseases
[15-17]. Their biomedical use is associated to their involvement in the pathogenesis of
many diseases; the fact that they are unlikely to elicit an allergic response and that they
are able to stimulate the immune system without the presence of a pathogen. Different
cytokines have been tested as treatments for various diseases. Interferon alpha (IFNα) is
one of the best characterized cytokines for human disease treatment  [18] and can be
naturally derived (leukocyte or lymphoblastoid derived) or recombinantly produced (E.
coli-derived). Therapeutic uses of IFNα include hepatitis B and C (antiviral), condyloma
(immunomodulation),  Kaposi's  sarcoma  (antiangiogenic)  and  hairy  cell-leukemia
(antitumor) [17, 18]. IL-2 is another example of a cytokine that has been obtained from
E. coli and evaluated as a therapeutic in bladder carcinoma and melanoma  [16, 17].
TNFα has been produced recombinantly in E. coli and different studies have revealed it
exhibits antitumor properties and strong hemodynamic effects. In fact, TNFα has been
used  to  treat  cancer  in  phase  III  studies  in  melanoma  patients  [19].  CCL4 induces
monocyte cell recruitment at inflammatory sites [20] but clinical studies are still being
conducted  to  confirm  the  pathophysiological  role  of  CCL4  as  an  active  factor  in
ischaemic  stroke,  as  a  neuroprotective  agent  or  as  an  anti-HIV  agent  [21,  22].
Additionally,  other cytokines have been explored as a potential  therapeutics,  such as
CCL5, IL-6, IL-7, IL-15, IFNβ [23-25] but only a few recombinant cytokines such as
G-CSF,  GM-CSF,  erythropoietin  or  IL-2 have been licensed for human use  [1,  26].
Despite all their appealing therapeutic properties, cytokines have significant drawbacks
for medical use, in particular their short half-life (minutes or hours), which implies the
administration of high doses, prompting toxicity and systemic effects as cytokines are
administrated intravenously. Further, high doses entail the expensive production of large
quantities [27, 28]. 
In this study, we have explored the ability of tumor necrosis factor alpha (TNF and
chemokine (C-C motif) ligand 4 (CCL4) produced as nanostructured functional IBs, to
act as immunostimulants and potential  adjuvants.  By using cytokines  in the form of
nanostructured IBs, we hope to overcome the fundamental difficulties of poor stability
and  short  half-life,  which  hinder  cytokine  use.  We  show  that  nanostructured
recombinant cytokines are easy to produce by cost-effective and highly reproducible
procedures. Furthermore, we provide detailed evidence in the model organism zebrafish
(Danio rerio), that they can be used in vivo as efficient immunostimulants or adjuvants,
either  injected  or  orally  administrated,  inducing  excellent  immune  protection  levels
against an otherwise lethal bacterial challenge. 
Materials and Methods
Bacterial strains and plasmids
Trout CCL4 sequence  (acc. number AY561709.1)  was used to design specific cloning
primers (Suppl. Table 1). The CCL4 full length was amplified from cDNA synthesized
from trout head kidney total RNA purified using TriReagent (Sigma). The PCR product
was excised from the gel, ligated into pET-30Xa/LIC vector (Novagen) and transformed
into E. coli DH5α (Invitrogen). The CCL4-pET-30 Xa/LIC was then purified using the
Nucleo-Spin  Plasmid  Quick-Pure  (Macherey-Nagel),  quantified  using  a  Nanodrop
ND-1000 (Thermo Scientific) and sequenced in order to check the sequence orientation.
Finally,  for recombinant  protein expression the CCL4-pET-30Xa/LIC was subcloned
into  E. coli BL21(DE3) pLysS strain. The bacterial strain used  for the production of
TNFα IBs  was  E. coli M15[pREP4] (Qiagen). This strain was transformed with the
TNFα-pQE30 vector (Qiagen) as described  [29]. CCL4-pET-30Xa/LIC and iRFP-H6-
pET22b were transformed into  E. coli BL21(DE3) for the recombinant production of
IBCCL4 and infrared fluorescent  protein,  IBiRFP-H6  respectively.  Note that  IBiRFP-H6 were
produced  as  control  nanoparticles  with  irrelevant  biological  activity  regarding
immunostimulation.  All  the  recombinant  proteins  contained a  His-tag  and  could  be
detected by western blot using an anti-His tag antibody (GenScript).
IBs production, purification and fluorescent labelling
The  E.  coli transformed  with  TNFα-pQE30,  CCL4-pET-30  Xa/LIC  and  iRFP-H6-
pET22b  were  cultured  in  LB  medium  supplemented  with  required  antibiotics.
Expression was induced when OD550 nm reached 0.5 for 3 h at 1 mM of IPTG (Panreac).
For  IB  purification  the  bacterial  cultures  were  processed  through  a  combination  of
enzymatic and mechanical disruption. First, lysozyme at 1 μg/ml (Roche) and PMSF at
0.4 mM (Roche) were added to bacterial suspensions and incubated for 2 h at 37 °C and
250 rpm. Then, the cells were frozen and thawed and Triton X-100 (Sigma) was added
(0.2 % (v/v)), the suspension was incubated 1 h under gentle agitation at RT. IBs were
harvested by centrifugation and resuspended in PBS (10 times concentrated with respect
to the original culture volume). Next, samples were incubated with DNAse at 0.6 µg/ml
(Roche), 1 h at 37 °C under agitation. Several freeze/thaw cycles were carried out until
no viable bacteria were detected. Samples were centrifuged at 15.000 x g for 15 min and
pellets containing purified IBs stored at -80 °C until use. The IBs were quantified by
western blot using an anti-His-tag antibody and the protein concentration was inferred
from a standard curve made with recombinant protein.
To visualize  IBTNFα and IBCCL4 by flow cytometry and confocal microscopy,  Atto-488
NHS  ester  (Sigma)  was  conjugated  at  a  molar  ratio  1:2  (protein/dye)  following
manufacturer’s  instructions.  Labeling  efficiency  was  calculated  using  Nanodrop
ND-1000. 
IBTNFα and IBCCL4 nanoparticle characterization
IBTNFα and IBCCL4 were characterized by Field Emission Scanning Electron Microscopy
(FESEM, Zeiss  Merlin).  The samples  were resuspended in distilled  water  at  a  final
concentration of 100 μg/ml and 20 µl were deposited on silicon chips and air dried O/N.
FESEM images  were  processed  using  the  software  ImageJ  software  v1.5  (National
Institute  of Health,  USA) length measures  of at  least  300 particles  per sample were
taken  and  size  distribution  graphs  were  generated  using  Past3  software  v3.03
(University of Oslo). Particle stability was evaluated under the same conditions found in
the trout gastrointestinal tract  [30]. The IBTNFα at 0.5 mg/ml were incubated in PBS at
pH 2.5 (adjusted with HCl) for 3 h and then in PBS at pH 8.0 (adjusted with NaOH) for
6 h at  RT under orbital  shaking.  Particle  thermostability  was also evaluated at  high
temperature. The IBTNFα at 0.5 mg/ml were incubated at 100 ºC for 30 seconds. Finally,
we  analyzed  the  stability  of  TNFα  IBs  after  lyophilization  and  storage  at  room
temperature.  IBTNFα were lyophilized  in  a  Telstar  Lyoquest-80 lyophilizer  for  8  h at
-80 ºC and stored at  RT for 3 weeks. The  IBTNFα were analyzed by FESEM and the
diameter and length of 300 nanoparticles were measured. Statistical differences were
analysed using a t-test (GraphPad Prism software v5, USA).
Cell Cultures
Zebrafish  ZFL cells  (CRL-2643,  ATCC)  were  cultured  in  DMEM  4.5  g/l  glucose
(Gibco), 0.01 mg/ml insulin, 50 ng/ml EGF, 5 % (v/v) of antibiotic/antimycotic, 10 %
(v/v)  heat  inactivated  FBS and 0.5 % (v/v)  heat-inactivated  rainbow trout  serum at
28 ºC  and  5  % CO2  as  described  before [31].  Adherent  rainbow  trout  head  kidney
macrophages (RT-HKM) were isolated from head kidney as described previously  [29]
and cultured in DMEM 4.5 g/l glucose supplemented with FBS (10 %) and 50 µg/ml
Primocin (Invivogen) at 16 ºC and 5 % CO2. Fully differentiated macrophages (day 5)
were used for uptake and gene expression experiments.
Gene expression analysis  
Rainbow  trout  macrophages  (RT-HKM)  were  stimulated  for  12  h  with  IB iRFP-H6
(10 µg/ml), LPS 10 µg/ml (Sigma), IBTNFα and IBCCL4 at different concentrations (5, 10
and 20 µg/ml and 0.01, 0.1 and 1 µg/ml, respectively). Total RNA was extracted using
TriReagent (Sigma) following manufacturer’s instructions and the RNA concentration
and quality  were evaluated  using the  Nanodrop ND-1000 and the  Bioanalyser-2100
with the RNA 6000 Nano Kit (Agilent Technologies) respectively. The cDNA synthesis
was  performed  with  1  µg  of  total  RNA using  SuperScript  III  reverse  transcriptase
(Invitrogen) and oligo-dT15 primer (Promega).  Quantitative real-time PCR was carried
out using SYBR Green I PCR Supermix (Bio-Rad), 250 nM of primers and 2.5  µl of
cDNA previously diluted (1:50 for target and 1:500 for the reference gene) in 10 µl of
final volume. The  primers included in the study are listed in Supplementary Table 1.
Elongation factor 1 alpha (EF1) was used as a reference gene and quantification was
done according to Livak method  [32]. The experiments were repeated 3 independent
times and all samples were run in triplicate. The results were analyzed using one-way
ANOVA followed by Tukey’s post-test (GraphPad Prism).
IBs uptake by ZFL and RT-HKM cells
Fluorescent IBTNFα and IBCCL4 were added to the ZFL and RT-HKM cell cultures at the
indicated doses and time, and the cells were analyzed by flow cytometry (BD FACS-
Canto) and confocal microscopy (Zeiss LSM 700). For the dose-response uptake assays,
the ZFL and RT-HKM cells were incubated with IBTNFα and IBCCL4 at different doses (5,
10 and 20 µg/ml) for 12 h. After treatment, the medium was removed and the cells were
washed with PBS to remove membrane bound particles. Each sample was treated with 1
mg/ml  trypsin  (Gybco)  for  15  min  to  discard  externally  attached  IBs  and  then
centrifuged at 300 x g for 5 min. Pellets were resuspended in 200 µl of PBS for flow
cytometry  analysis.  Experiments  were performed in  triplicate  and 10,000 events  for
each  sample  were  taken.  The  results  were  analyzed  with  one-way  ANOVA and  a
Tukey’s post-test. For confocal microscopy, the ZFL and RT-HKM cells were incubated
with 20 µg/ml of IBTNFα and IBCCL4 for 12 h. After three PBS washes, the nuclei were
labeled with Hoechst 33342 (10 µg/ml) and the membranes with CellMask (5 µg/ml).
The images were analyzed with Imaris software v8.1 (Bitplane AG).
Animals
Adult wild-type zebrafish (Danio rerio) and rainbow trout (O. mykiss) were maintained
under a 12 h light/12 h dark cycle at 28 ± 0.5 ºC and 17 ± 0.5 ºC, respectively and fed
daily with a commercial diet at 0.5 % ratio. All experimental procedures were approved
by to  the  Ethical  Committee  of  the  Universitat  Autònoma de  Barcelona  (Reference
1555) in agreement with the International Guiding Principles for Biomedical Research
Involving Animals (EU 2010/63).
In vivo biodistribution of IBTNFα in rainbow trout
Animals (122.3 ± 17.13 g body weight) were anesthetized and i.p. injected with 300 µl
of IBTNFα-Atto488 (5.5 mg/kg) or 300 µl of PBS. After 24, 48 and 72 h fish (n = 4) were
sacrificed by overdose of MS-222 (Sigma) and head kidney and spleen were removed.
Adherent  monocytes/macrophages  were  isolated  from  head  kidney  and  spleen  as
described before [29]. In parallel, a piece of tissue was dissected and stored at -80 ºC for
gene expression analysis. After 24 h of primary cell culture, cells were analyzed both by
flow cytometry and confocal microscopy.
In vivo immunization with TNFα and CCL4 IBs
Adult zebrafish (0.64 ± 0.17 g body weight) were transferred to an isolated system and
acclimatized  1  day  before  each  experiment.  Pseudomonas  aeruginosa (PAO1)  was
cultured and grown as previously described [33]. For IBs and PAO1 injection, fish were
anaesthetized with 166 ppm of MS-222 (Sigma) and intraperitoneally (i.p) injected with
either 20 µl of IBs or PBS. At 7 or 30 days post-injection, fish were challenged by i.p.
injection  with 20 µl  of  P. aeruginosa PAO1 (LD50)  at  4  x 107 cfu/animal  and their
survival was followed for 7 days.  Survival curves were analyzed using the Kaplan–
Meier method and the differences were evaluated using the log-rank test  (GraphPad
Prism). Relative percentage of survival (RPS) was calculated according to RPS (%) =
[(1 − mortality treated group)/mortality control group] × 100.
Oral administration of TNFα IBs 
Rainbow  trout  (135.3  ±  16.8 g  body  weight)  were  starved  three  days  before  the
administration of the IBs. Then, animals were anesthetized, orally intubated and 200 µl
of  IBTNFα-Atto488 (7.49  ± 0.97  mg/kg) were administrated.  After 24 h rainbow trout
were sacrificed by overdose of anesthesia and the intestine was removed and maintained
in  DMEM.  The  intestine  was  divided  in  three  sections:  pyloric  caeca,  midgut  and
hindgut  (hindgut  section  was  discarded).  Cells  from the  intestine  were  obtained  by
enzymatic  digestion  with collagenase  (0.15 mg/ml,  Invitrogen)  for  2  h at  RT.  After
digestion, the intestine pieces were mechanically disrupted with a cell strainer and the
resulting homogenate was centrifuged 15 min at 450 x g at 4 ºC. Then, the pellet was
washed,  resuspended  in  DMEM  and  analyzed  by  flow  cytometry  (100,000
events/sample). Additionally, pyloric caeca and midgut samples (n= 6) were embedded
in  Tissue-Tek  O.C.T.  Compound  (Sakura),  frozen and stored  at  -80  ºC.  Sections  of
0.6 µm were obtained at -20 ºC with a Cryostat (Leica CM3050S). Fluoroshield (Sigma)
was added to every slide and all samples were analyzed by confocal microscopy.
Results
1. Structural characterization of TNF (IBTNFα) and CCL4 (IBCCL4) IBs. 
Two different cytokines, CCL4 and TNFα, were successfully produced in E. coli as IBs
(Figure  1A).  The  morphology  and  size  of  both  biomaterials  were  characterized  by
FESEM and are shown in Figure 1A. The shape of the IBs differs between the two
cytokines.  IBTNFα is cylindrical with a smooth surface and several circular pores, and
IBCCL4 is also spherical but with a more irregular surface. Similar morphology has been
described previously for other protein nanoparticles purified from IBs [11]. The size of
IBTNFα and  IBCCL4 also  differed  significantly.   IBTNFα diameter  was  between  380  to
900 nm with  a  mean  size  of  623.3  ±  105  nm and  length  ranging  between  750  to
2000 nm with a mean length of 1134.6 ± 196.6 nm (Figure 1B (i -ii)). The IBCCL4 have a
smaller  size ranging between 220 to 850 nm with a mean size of 383.9 ± 82.3 nm
(Figure 1B (i)). Furthermore, the purified IB yield varied between proteins under the
same production conditions; we obtained 18 times more IBTNFα than IBCCL4 (18 ± 5 mg/l
and 1.2 ± 0.92 mg/l, respectively). 
2. Uptake of IBTNFα and IBCCL4 by ZFL and RT-HKM
To explore the interaction of these IBs with cells, we analyzed the uptake of IBTNFα and
IBCCL4 by zebrafish liver cells (ZFL) and by trout primary macrophages (RT-HKM). The
results showed that ZFL cells were able to uptake both IBTNFα and IBCCL4 very efficiently
(Figure 2A) and the dose-response assays showed that all concentrations of IBTNFα and
IBCCL4 were easily endocyted by ZFL cells (e.g. 97 ± 0.5 % and 99 ± 0.1 % positive cells
at  10  µg/ml,  respectively)  (Figure  2A).  Also  primary  cultures  of  macrophages  (RT-
HKM) were able to uptake the IBTNFα and IBCCL4 at the same levels as ZFL cells (96 ±
1.4 % and 98 ± 0.9 % positive cells at 10 µg/ml, respectively) (Figure 3A). When we
analysed the Mean Fluorescence Intensity (MFI) of the dose response experiments we
observed a good correlation between IB dose and MFI both in ZFL and HKM cells
(Supp. Figure 1). Finally, the confocal microscopy images enabled the visualization of
the uptake by ZFL and the RT-HKM cells (Figure 2B and 3B (i)) and the 3D images
demonstrated the complete internalization of IBs in ZFL and in RT-HKM (Figure 2B
and 3B (ii - iv)).
3. Bioactivity of IBTNFα and IBCCL4 
In order to evaluate the capacity of IBs to activate the immune response in specific
immune cells, we stimulated trout macrophages (RT-HKM) with IBTNFα, with IBiRFP-H6 as
a control of an IB without a relevant immune role, and with LPS as a typical strong
activator  of  the  immune  response  [34].  IBTNFα  were  able  to  stimulate  RT-HKM  by
increasing the gene expression of cytokines and regulators of inflammation. We showed
that treatment with IBTNFα stimulated the expression of pro-inflammatory cytokines such
as  TNFα,  IL-6,  IL-1β  and  IL-8  (Figure  4).  We  also  analyzed  genes  related  to  the
modulation  of  the  inflammation  process,  the  inhibition  of  the  cytokine  receptor
signaling and the  extracellular matrix remodeling, such as COX-2, CAMP-1, SOCS3
and MMP9. The results showed that IBTNFα were able to increase the expression of these
genes at different IBTNFα concentrations, but not in a dose-dependent manner (Figure 4).
We did not observe an effect related to the sequence of the protein forming IBs, at least
there were no differences in the gene expression between IBTNFα and IBiRFP-H6 treatments.
However, IBTNFα were able to induce an increase in gene expression comparable to that
of commercial LPS. Similar results were obtained when we stimulated RT-HKM with
IBCCL4 but  at  lower  doses.  The  results  showed  that  the  IBCCL4 were  able  to  induce
expression of all  the genes analyzed and gene expression was significantly different
from LPS and IBiRFP-H6 for IL-6, SOCS3 and CAMP1 (Suppl. Figure 2), indicating that
the nature of the protein had an effect on the immunostimulation. However, this event
could not be observed in other genes: TNFα, IL-1β, IL-8, COX-2 and MMP9. 
4. In vivo biodistribution of IBTNFα 
Next, to study whether or not macrophages were the targets of the IBTNFα in vivo we
injected animals with IBTNFα-Atto488 IBs. In these experiments we decided to work only
with IBTNFα since, as mentioned before, the yield of IBTNFα was higher than that of IBCCL4
and this enabled us to do the in vivo experiments. Worth to mention that due to the small
size of zebrafish, that did not allow us to perform this kind of  in vivo biodistribution
experiments,  we used  another  teleost  (trout)  thus  maintaining  the  physiological  and
immunological  coherence.  By  flow  cytometry,  fluorescent  cells  were  significantly
detected in spleen at 48, 72 and 96 h post-injection (Figure 5A). Fluorescent positive
cells were also found in phagocytes in the head kidney at the same time points (Figure
5A),  although  at  lower  levels  than  in  the  spleen  (e.g.  at  48  h  post-injection,  the
percentage of fluorescent cells in the spleen was 78 ± 7.5 % while in the head kidney
was 22.9 ± 2.4 %). The total number of fluorescent cells detected both in spleen and
head kidney decreased along the time (Figure 5A) although they could be detected at
least  until  10  days  after  the  injection  (data  not  shown).  The  presence  of  IBTNFα in
macrophages in both immune organs was also detected by confocal microscopy at 48,
72 and 96 h post-injection (Figure 5B and 5C (i)). Again, the number of IBTNFα positive
macrophages in head kidney was lower than in phagocytes from the spleen (Figure 5B
and 5C (i)). The complete internalization of the nanoparticles and their location in the
cytoplasm  of  the  cells  was  demonstrated  with  z-stack  and  membrane  staining  in
macrophages from spleen and head kidney (Figure 5B and 5C (i - iii)).
5. In vivo immunization with IBTNFα and IBCCL4.
We next evaluated whether the IBTNFα, IBCCL4 and IBiRFP-H6 were able to protect against a
model lethal challenge with  P. aeruginosa. We obtained higher survival rates in fish
treated  with  IBTNFα and  IBCCL4 compared  to  those  animals  treated  with  IBiRFP-H6
containing a control protein (100 % RPS of IBTNFα and 91 % RPS of IBCCL4) (Figure 6A
(i  -  ii)).  Interestingly,  the  protection  levels  achieved  with  IBCCL4 were  significantly
higher at half of the dose of IBTNFα (Figure 6B (ii)). The high viscosity of IBCCL4 solution
did not allow us to use this IB at the highest dose, however with a quarter of the IBTNFα
dose we obtained excellent protection levels (survival of 91 % with  IBCCL4 at 75 µg
compared with survival of 100 % with IBTNFα at 300 µg) and these differences were still
observed at a lower dose (150 µg of  IBTNFα) (Figure 6B (i)).  When we compared the
survival obtained with the IBiRFP-H6  treatment  (non-immunologically relevant protein),
the results  showed significant  differences  with both cytokine  IBs treatments  (IBTNFα,
p<0.01 and IBCCL4, p<0.05) (Figure 6). Finally, to demonstrate that cytokines and not E.
coli contaminants such as endotoxin, peptidoglycans or nucleic acids, were the main
responsibles of immune activation we performed the bacterial challenge 30 days after
the injection of IBTNFα (Suppl. Figure 3) when the early innate immune response is not
active and the observed increased in the survival, relays only on the adaptive immune
response. We observed that the survival was clearly higher in the animals injected with
the IBTNFα (75 % RPS) 30 days after the treatment with the IBTNFα (Suppl. Figure 3).
6. In vitro stability tests of IBTNFα
It is well documented that the IBs are stable in vitro under a wide range of conditions,
for  example:  at  different  temperatures  (-80  ºC,  4  ºC,  25  ºC,  and  37º  C)  or  under
lyophilization  conditions  (12  h  at  -80  ºC)  [5].  Since  we  also  wanted  to  test  their
suitability for oral administration, we determined IB stability under gastrointestinal pH
conditions  [30]. We also tested thermostability to demonstrate  stable shelf  life (high
temperature and lyophilization). In general, we observed a similar shape of IBTNFα under
different pH or the temperature treatments compared to untreated control (Figure 7A
and B) and a similar diameter and length distribution between control and pH treatment
(Figure 7A (ii - iii)). We only found significant differences in the diameter and length
between the high temperature (diameter: 666.2 ± 84.2 nm, t- test,  p < 0.0001; length:
947.1 ± 186.4 nm, t- test, p < 0.0001) and the control condition (diameter: 623.3 ± 105
nm; length:  1134.6  ±  196.6  nm)  (Figure  7B (ii  -  iii)).  To  further  explore  why the
temperature  was  shortening  the  IBs,  we  checked  the  presence  of  protein  in  the
supernatants of samples submitted to high temperature. The western blot confirmed that
free/soluble protein was not present in the supernatants (data not shown) discarding our
hypothesis of a potential massive release of protein from the nanostructure due to the
drastic environmental change. Despite the size differences in the IBs incubated a high
temperature,  both IBs submitted to pH and temperature treatments were still  able to
stimulate the gene expression of immune related genes at equivalent levels to the same
IBs under control conditions (Suppl. Figure 4). We also evaluated whether fluorescent
IBTNFα were able  to  maintain  their  fluorescence  after  incubation  at  low/high pH. As
shown in  Figure  7C,  the  RT-HKM were  able  to  endocytose  the  pH treated  IBTNFα-
Atto488  IBs  without  differences  with  respect  to  control.  Importantly,  fluorescence
intensity remained the same after the pH treatment, which would allow us to monitor
fluorescent TNFα materials administrated orally.  Finally,  we analyzed the stability of
IBTNFα after lyophilization, showing that this procedure did not modify the morphology
as  shape,  size  and  porosity  were  maintained  (Suppl.  Figure  5A  and  5B  (i-ii)).
Lyophilization did not affect the ability of the  IBTNFα to protect animals against a  P.
aeruginosa lethal challenge and animals injected with lyophilized and non-lyophilized
IBTNFα survived without a significant difference between treatment groups (83 % of RPS
and 62 % of RPS, respectively) (Figure 7D). 
7. Oral administration of fluorescent IBTNFα
First we demonstrated  in vitro excellent mechanical and functional stability properties
of the  IBTNFα under those conditions mimicking the traffic through the gastrointestinal
tract. Next, we tested  in vivo whether the orally administrated  IBTNFα could reach the
mucosal tissue and the cells within the intestinal mucosa. We intubated adult animals
and we administrated IBTNFα-Atto488 IBs into the stomach. After 24 h we dissected the
intestine to perform cytometry and tissue sections. We worked with the pyloric caeca
and the midgut  segments  as they are the main  areas of nutrient  absorption  [35].  To
perform the flow cytometry analysis we pooled the cells from the pyloric caeca and the
midgut and we detected 20.2 ± 7.4 % of fluorescent cells (Figure 8A). This is a high
percentage considering that no cell type was separated by other means such as specific
antibody labeling and cell sorting [36]. The tissue sections allowed the visualization of
the IBTNFα-Atto488 IBs both in cells of the pyloric caeca and cells of the midgut (Figure
8B). In the pyloric caeca the presence of  IBTNFα-Atto488 IBs was qualitatively more
abundant  than  in  the  midgut  sections.  The  positive  cells  in  the  pyloric  caeca  were
mainly located in the villi base and in the submucosa, while in the midgut sections the
IBTNFα-Atto488 IBs were mainly observed in the villi apex and in the lamina propria
(Figure  8B  (ii-iii)).  The  IBs  detected  in  the  intestinal  mucosa were  able  to  form
intracellular agglomerates of different sizes in the cytosol both in the pyloric caeca and
midgut sections (Figure 8B). 
Discussion
We have used two model  cytokines  and a model  organism  to test  whether  cytokine
nanoparticles  organized  as  functional  IBs  were  suitable  as  immunostimulants  or
adjuvants for biomedical applications. In this work, we provide a proof of concept on
the functionality and suitability of protein nanoparticles for their future possible use in
human health. IBs are excellent candidates to be used as adjuvants, being highly stable,
non-toxic and fully biocompatible under a wide range of conditions  [7]. As shown in
this  study,  IBTNFα maintained  its  stability  and  functionality  after  incubation  under
different  conditions  of pH and temperature,  supporting  the notion that  IBs made of
recombinant cytokines do not require additional encapsulation systems, since they are
extremely  stable  in  the  nanostructured  conformation.  This  is  in  sharp  contrast  to
immunostimulants made with native cytokines that are extremely unstable (half-life of
minutes). Indeed, when oral administration of such vaccines is desired, often the design
has to include additional nanoencapsulation systems that provide protection under  in
vivo conditions  [37,  38].  A variety of encapsulation methods,  to protect  vaccines or
cytokines against degradation in the intestinal tract have been reported with promising
results but, in most cases they are not yet cost effective [37, 39]. As IBs, cytokines are
not only structurally stable, but they maintain their functional properties intact. Both of
our prophylactic IBs, IBTNFα and IBCCL4, were able to induce a typical immune response
in  vitro and  were  also  able  to  efficiently  protect  zebrafish  from  a  lethal  bacterial
infection. In this study we have obtained higher survival percentages when injecting IBs
made with immune-relevant  proteins.  In fact,  the main responsible  of the protection
observed when injected IBTNFα is the nanostructured cytokine as has been demonstrated
in the long-term protection experiments. However, the protection conferred by the IBs is
probably  the  result  of  their  nanostructure,  the  sequence  of  the  building  protein,
combined with their compositional complexity (LPS, lipids, PGN and nucleic acids).
The high protection levels of IBCCL4 at a lower dose compared to that of IBTNFα could be
due to the differential presence of co-purified bacterial components (LPS, lipids, PGN
and nucleic  acids)  during both IBs purification procedures.  IBTNFα and IBCCL4 confer
higher  survival  rates  in  comparison  to  other  IBs  made  with  non-immune  relevant
proteins  (IBiRFP-H6).  Importantly,  the  IBs  final  composition  can  be  modulated  using
different  E.  coli strains  (e.g.  endotoxin  free  strains)  together  with  “final  purpose”-
adapted  purification  methods  [7,  40].  Our results  strongly  suggest  that  the
immunological  nature  of  the  protein  increases  the  protection  conferred  by  the  IBs,
opening the way to explore other proteins, such as antigenic viral proteins for vaccine
design. 
From a commercial point of view it is also important to demonstrate the feasibility of
the  cytokine  IBs  pipeline  production.  In  this  context,  the  IBs  did  not  modify  their
structural  or  functional  properties  after  lyophilization,  meaning  that  lyophilized  IBs
would not  require  cold-chain maintenance  and could be stored and used at  ambient
temperatures. All these characteristics lower the cost of production of the final products
and provide easy and convenient handling. Both, the structural and functional stability
together  with versatility  would be the key for a  future biomedical  use of  cytokines
produced as IBs. When injected,  IBs were able to reach and accumulate  in immune
relevant-organs (spleen and head kidney) and -cells (macrophages), as reported by other
authors [33, 41]. The spleen is the major filtering organ for removal of foreign agents
[42] and together with head kidney, are the main lymphoid organs in teleosts  [43]. In
addition,  these  are  also  the organs  where  phagocytes  are  more  abundant  and
importantly, the spleen is the main organ for antigen presentation in teleosts [44, 45]. In
mammals the spleen is also the main organ of antigen removal and recognition together
with the lymph nodes and the thymus [46]. 
Moreover, our results strongly support the view that IBs could be excellent candidates
for oral administration. After oral administration IBs were clearly uptaken and located
in the villi base and submucosa within the pyloric caeca section and, in the villi apex
and lamina propria within the midgut.  Oral immunization provokes the activation of
lymphocytes T and B and the antibody production in the mucosal secretions (e.g. skin
mucus, bile, intestine mucus) [35, 47]. The main immune tissue involved in the uptake
and processing of orally administrated antigens is the gut-associated lymphoid tissue
(GALT). Teleosts possess the whole set of immune cells and molecules required for a
GALT local immune response, although the global GALT structure is more diffuse than
in mammals [48]. In teleosts the main effector sites in GALT are located in the lamina
propria  (LP)  and  in  the  intraepithelial  lymphocyte  compartments  (IEL)  while  the
classical effector sites (Peyer’s patches and mesenteric lymph nodes MLNs) have only
been  described  in  mammals  [49].  Fish  do  not  have  these  structures  but  possess
extrafollicular antigen presenting cells (APCs) that have been also described as inducer
cells [50]. Accordingly, we detected fluorescent nanoparticles in the LP (midgut) and in
the villi apex where IEL are located. The strong uptake ability of the midgut has an
immune value, because it has been shown that antigens could be transported towards the
local as well as systemic immune system [48,  51]. Based on our results, the IBs have
been  uptaken  in  the  intestine  maybe  by  IEL and  APCs  and  stored  intracellularly,
probably stimulating mucosal immune responses. The nanostructure and stability of the
IBs,  together  with the  good levels  of  absorption  by the  intestinal  mucosa  favor  the
possibility of oral use.  
Conclusions
In  this  study we were  able  to  produce  nanostructured,  functional  and  highly  stable
cytokines  as  inclusion  bodies  (IBs),  generating  a  fully  biocompatible  material  with
biomedical applicability,  without further encapsulation needs. These cytokines,  IBTNFα
and IBCCL4, interact with relevant immune cells and tissues both when intraperitoneally
injected or orally administrated, and provide in vivo excellent protection levels against a
model  lethal  infection.  These new biomaterials  pave the way for using recombinant
cytokines for therapeutical purposes in a more efficient and cost effective way.
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Figures
Figure 1. Characterization of the inclusion bodies (IBs) nanoparticles. (A) FESEM 
images of IBTNFα and IBCCL4.  (B) Size distribution of the IBTNFα and IBCCL4, diameter (i) 
and length (ii).
Figure 2. Uptake of IBTNFα and IBCCL4 by ZFL cells.  (A) Dose-response. Cells were
incubated with 5 to 20 µg/ml IBTNFα and IBCCL4 for 12 h. Data represent mean ± SD (n =
3). Differences were analyzed using one-way ANOVA and Tukey’s post test. Significant
differences against control: ***, p < 0.0001. (B) Confocal microscopy images of IBTNFα
and IBCCL4 (green) uptake by ZFL cells (i). Cells were incubated 12 h with 10 µg/ml of
IBTNFα and IBCCL4. Cell membranes are shown in red and nuclei in blue (ii). Digitalized
image of the same cells, z-stack (iii) and whole-membrane (iv).
Figure 3. Uptake of IBTNFα and IBCCL4 by RT-HKM cells.  (A) Cells were incubated
with 5 to 20 µg/ml  IBTNFα and IBCCL4  for 12 h.  Data represent  mean  ±  SD (n  = 3).
Differences were analyzed using one-way ANOVA and Tukey’s post test. Significant
differences against control: ***, p < 0.0001. (B) Confocal microscopy images of IBTNFα
and IBCCL4 (green) uptake by RT-HKM cells  (i).  Cells  were incubated 12 h with 10
µg/ml of IBTNFα and IBCCL4. Cell membranes are shown in red and nuclei in blue (ii).
Digitalized image of the same cells, z-stack (iii) and whole-membrane (iv).
 
Figure 4. Gene expression analysis in RT-HKM cells stimulated with IBTNFα, LPS
and IBiRFP-H6. Cells were incubated with 10 µg/ml of IBiRFP-H6, 10 µg/ml LPS and 5, 10
and 20 µg/ml of IBTNFα for 12 h. The gene expression was analyzed by Q-PCR. Data
represent mean ± SD (n  = 3). Differences were analyzed using one-way ANOVA and
Tukey’s post test. Significant differences respect control (*,  p<0.05; **,  p<0.01; ***,
p<0.001) and LPS (a, p<0.05).
Figure 5. In vivo uptake of IBTNFα by phagocyte cells from spleen and head kidney.
(A) Quantification of IBTNFα uptake by phagocytes from spleen, SP (red triangles) and
head kidney, HK (green squares) after 48, 72 and 96 h post-injection. Data represent
mean ± SD (n = 4). Confocal images of phagocytes from spleen (B) and head kidney
(C) at 48, 72 and 96 h post-injection (i). 3D image analysis of IBTNFα uptake (z-stack)
(ii) and whole-membrane reconstruction (iii).
Figure 6. Survival of the zebrafish after i.p. injection with IBTNFα, IBCCL4 and IBiRFP-
H6 and challenge with P. aeruginosa. (A) The IBTNFα and IBiRFP-H6 dose was 300 µg and
the IBCCL4 dose 75 µg, and (B) the IBTNFα and IBiRFP-H6  dose was 150 µg and the IBCCL4
dose 75 µg. (i) Table showing the relative percentage of survival (RPS). (ii) Zebrafish
survival curves after i.p. injection with IBTNFα, IBCCL4 or IBiRFP-H6 and challenged with P.
aeruginosa PAO1 (LD50) (4 x 107 cfu/dose) (n = 15). Untreated zebrafish that had been
infected  with  PAO1  were  used  as  mortality  control. Significant  differences  were
analyzed using the log-rank test; **, p < 0.01; ***, p < 0.0001.

Figure  7.  Characterization  of  IBTNFα particle  stability  under  extreme  pH,
temperature  and  lyophilization  conditions.  (A)  FESEM  images  and  (B)  size
distribution, diameter (i) and length (ii)) of  IBTNFα at different pH (pH 2.5 for 3 h and
then pH 8 for 6 h) and high temperature (C) Percentage of fluorescent cells and Mean
Fluorescent  Intensity  (MFI)  of  RT-HKM  after  stimulation  with  TNFα-Atto488  IBs
previously incubated at pH 2.5 for 3 h and then pH 8 for 6 h. (D) Immunization of
zebrafish with lyophilized IBTNFα  (L). Survival curves after i.p. injection of control and
lyophilized  IBTNFα after  the  challenge  with  P.  aeruginosa PAO1  (LD50)  (3.4x107
cfu/dose) (n = 15). Untreated zebrafish that had been infected with PAO1 were used as
mortality  control.  The  control  and  lyophilized  IBTNFα dose  was  300  µg.  Significant
differences were analyzed using the log-rank test; **, p < 0.01; ***, p < 0.0001. 
Figure 8. In vivo uptake of IBTNFα by cells of the intestinal mucosa. (A) Percentage of
fluorescent cells in animals intubated with 1 µg/fish of  IBTNFα-Atto488 IBs after 24 h.
Data  represent  mean  ±  SD  (Control,  n  = 5  individuals,  IBTNFα,  n =  9  individuals).
Differences were analyzed using t-test. Significant differences respect to control ***,
p<0.001. (B)  Confocal images of intestine cells from pyloric caeca and midgut 24 h
post-intubation. Control (i), IBTNFα (ii), and IBTNFα at higher magnification (iii). White
arrows indicate the IBTNFα -Atto488 IBs. 
Supplementary Tables and Figures
Table S1. Rainbow trout primers for Q-PCR and CCL4 cloning.
 
Figure S1. Mean fluorescent intensity (MFI) in the uptake of the IBs. Dose-response
in A) ZFL and B) RT-HKM. Cells were incubated with 5 to 20 µg/ml of IBTNFα or IBCCL4
for 12 h. The gene expression was analyzed by Q-PCR. Data represent mean ± SD (n =
3). Differences were analyzed using one-way ANOVA and Tukey’s post-test. Significant
differences respect to control: a, p<0.001; b, p<0.01 and c, p<0.05, and between doses:
*, p<0.05; **, p<0.01; ***, p<0.001.
Figure S2. Analysis of the gene expression in RT-HKM cells stimulated with IBiRFP-
H6, LPS and IBCCL4. Cells were incubated with 10 µg/ml of IBiRFP-H6, 10 µg/ml LPS and
0.01, 0.1 and 1 µg/ml of IBCCL4 for 12 h. The gene expression was analyzed by Q-PCR.
Data represent mean ± SD (n = 3). Differences were analyzed using one-way ANOVA
and Tukey’s post-test. Significant differences respect to IBiRFP-H6 (a, p<0.001; b, p<0.05)
and LPS (*, p<0.05; **, p<0.01; ***, p<0.001).
Figure S3. Survival of the zebrafish after i.p. injection with  IBTNFα and  challenge
with  P.  aeruginosa. Zebrafish  survival  curves  after  i.p.  injection  with  IBTNFα and
challenged with  P. aeruginosa PAO1 (LD50) (2.4 x 107 cfu/dose) (n = 19) at 30 days
post-injection. The IBTNFα dose was 300 µg. Untreated zebrafish that had been infected
with PAO1 were used as mortality control. Significant differences were analyzed using
the log-rank test; *, p < 0.05.
 Figure S4. Analysis of TNFand IL1 gene expression by Q-PCR in RT-HKM
cells stimulated with IBTNFα incubate at different pH and temperature conditions.
Cells were incubated with 10 µg/ml of IBTNFα pH control, IBTNFα pH, IBTNFα temperature
control (T control) and IBTNFα temperature (T). Data represent mean ± SD (n = 4). 
Figure S5. Characterization of lyophilized IBTNFα.  (A) FESEM images and (B) size
distribution of the control and lyophilized IBTNFα, diameter (i) and length (ii). 
